BofA says BridgeBio's infigratinib is practice-changing, reiterates Buy with $104 price target

BofA views BridgeBio's infigratinib as practice-changing and a key contributor to the company's next phase of growth, reiterating a Buy rating with a $104 price target. BofA notes BridgeBio raised its forecast to $3B+ and sees upside in hypochondroplasia as largely overlooked.

Detected & updated continuously · Source: Nebula